Illumina, Inc. vs Lucid Group Inc — how do they compare? Illumina, Inc. trades at $264.95 (market cap $39.95B), while Lucid Group Inc trades at $3.85 (market cap $1.51B). The key difference: Illumina, Inc. is far larger — about 26.5× Lucid Group Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Lucid Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Lucid Group Inc for 45 Days on average.
| ILMN | LCID | |
|---|---|---|
Market Cap | $39.95B | $1.51B |
Volume | 3,169,503 | 12,333,745 |
Sector | Health | Consumer Cyclical |
52-Week High | $293.69 | $21.92 |
52-Week Low | $91.00 | $3.82 |
Typical Hold Time | 83 Days | 45 Days |
Enterprise Value | $41.31B | $4.40B |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
Lucid Group (LCID) trades at $3.89, down 6.49% in the last session, reflecting ongoing investor concerns about the company's financial performance. The stock shows bearish technical signals with negative moving averages and faces fundamental challenges including consecutive quarterly earnings misses, negative profit margins of -249.21%, and substantial cash burn. Recent developments include strategic partnerships for autonomous vehicle deployment in Europe but also product delays and cost-cutting initiatives targeting $1.4 billion in savings.
The outlook remains challenging with significant execution risks and negative cash flow trends. While analyst consensus suggests potential upside to a $7.60 price target, the high proportion of hold ratings (66.67%) indicates caution. Key risks include continued cash burn, competitive pressures in the EV market, and execution of turnaround plans. The company's survival depends on successful cost management and timely product launches.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →